Development of humanized antibodies as cancer therapeutics
- 31 May 2005
- Vol. 36 (1) , 84-95
- https://doi.org/10.1016/j.ymeth.2005.01.008
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003
- A clinical and scientific overview of tositumomab and iodine I 131 tositumomabSeminars in Oncology, 2003
- Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containingd-Amino AcidsBioconjugate Chemistry, 1999
- 90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution StudiesBioconjugate Chemistry, 1998
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996
- The coming of age of cancer radioimmunoconjugatesImmunology Today, 1993
- Quantitative analysis of cell surface HLA structures by means of monoclonal antibodiesHuman Immunology, 1980
- Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific ActivityNature, 1962